1. Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial

   Chamuleau, M. E. D., Burggraaff, C. N., Nijland, M., Bakunina, K., Mous, R., Lugtenburg, P. J., Dierickx, D., van Imhoff, G. W., Vermaat, J. S. P., Marijt, E. A. F., Visser, O., Mandigers, C., Bilgin, Y. M., Beeker, A., Durian, M. F., van Rees, B., Bohmer, L. H., Tick, L. W., Boersma, R. S., Snijders, T. J. F., Schouten, H. C., Koene, H. R., de Jongh, E., Hijmering, N., Diepstra, A., van den Berg, A., Arens, A. I. J., Huijbregts, J., Hoekstra, O., Zijlstra, J. M., de Jong, D. & Kersten, M. J., 19-Dec-2019, In : Haematologica.

   Research output: Contribution to journal › Article › Academic › peer-review

2. Rituximab-PECC induction followed by Y-90-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

   Dutch HOVON Grp, 10-Jul-2019, In : British Journal of Haematology. 9 p.

   Research output: Contribution to journal › Article › Academic › peer-review

3. Overall and disease-specific survival of Hodgkin lymphoma survivors who subsequently developed gastrointestinal cancer

   Rigter, L. S., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Zijlstra, J. M., van Imhoff, G. W., Poortmans, P. M. P., Beijert, M., Lugtenburg, P. J., Visser, O., Snaebjornsson, P., van Eggermond, A. M., Aleman, B. M. P., van Leeuwen, F. E. & van Leerdam, M. E., Jan-2019, In : Cancer medicine. 8, 1, p. 190-199 10 p.

   Research output: Contribution to journal › Article › Academic › peer-review

4. Tumour uptake of 89Zr-alemtuzumab compared to 111In-IgG in human non-Hodgkin's B-cell lymphoma bearing mice

   Sturkenboom, M. G. G., Lub-De Hooge, M. N., Dierckx, R. A. J. O., Van Imhoff, G. W., Kluin-Nelemans, H. C. & Kosterink, J. G. W., 1-Oct-2010, p. 289. 1 p.

   Research output: Contribution to conference › Abstract › Academic

5. Phase I dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: The HOVON/LLPC Transplant BRaVE study

   Hagenbeek, A., Mooij, H., Zijlstra, J., Lugtenburg, P., van Imhoff, G., Nijland, M., Tonino, S., Hutchings, M., Spiering, M., Liu, R., van Tinteren, H. & Kersten, M. J., 31-Mar-2019, In : Haematologica. 104, 4, p. e151-e153 3 p.

   Research output: Contribution to journal › Letter › Academic › peer-review

View all (124) »